About Instylla
Instylla is a Healthcare company based in United States founded in 2017. Hydrogel technology is developed for embolization therapy applications. It operates on a HealthTech model. Instylla has raised $85.51 million across 4 funding rounds from investors including Delos Capital, Excelestar Ventures and Ascension Ventures. The company has 26 employees. Instylla offers products and services including Embrace Hydrogel Embolic System and Tembo Embolic System. Its focus areas include Medical Devices and Interventional Radiology. Its legal entity is Instylla, Inc.
Company details
Instylla is focused on the development of next-generation liquid embolics for interventional radiology. Applications are primarily targeted at interventional oncology and peripheral hemostasis. Solutions like Embrace Hydrogel Embolic System are designed for embolization of hypervascular tumors in peripheral arteries. The company aims to advance medical procedures through innovative embolic systems.
- Headquarters United States
- Employees 26
- SectorsHealthcare
- Phone•••• ••••
- Website instylla.com
- Social LinkedIn X
- Legal Name Instylla, Inc.
- Total Equity Funding$85.51M (USD)
in 4 rounds
- Latest Funding Round$21.73M (USD), Series B
Jul 2025
- InvestorsDelos Capital
& 7 more
- Employee Count26
Products & Services of Instylla
Instylla offers a comprehensive portfolio of products and services, including Embrace Hydrogel Embolic System and Tembo Embolic System.
Used for embolization of hypervascular peripheral tumors.
Designed for embolization in interventional radiology applications.
Funding Insights of Instylla
Instylla has successfully raised a total of $85.51M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $21.73 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $85.51M
- Total Rounds 4
- Last Round Series B — $21.73M
- First Round $8.08M
(Jun 2017)
- Investors Count 8
All 4 funding rounds of Instylla with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2025 | $21.73M | Series B | – | – | – |
| Aug 2023 | $30.28M | Series B | – | Delos Capital | |
| Oct 2020 | $25.43M | Series B | – | Excelestar Ventures, Sparta Group | – |
| Jun 2017 | $8.08M | Series A | – | – | – |
8 investors in total: 8 institutional.
Investors in Instylla
Instylla has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Delos Capital, Excelestar Ventures and Ascension Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Delos Capital is engaged in private equity and financial advisory services. | deloscap.com | New York City, United States | ||
Late stage tech-focused VC firm funding companies in the US | excelestarventures.com | Andover, United States | ||
Strategic investments in healthcare technologies and data innovations. | ascensionventures.org | |||
| chv.vc | ||||
| amedventures.com | ||||
Sparta Group LLC is engaged in investment management services. | spartagroupllc.com | Stoneham, United States | ||
Medical innovations are accelerated from concept to commercialization by Incept. | inceptllc.com | Bedford, USA | ||
| spartagroup.com |
Investor details for Instylla
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Instylla
6 people are tracked at Instylla (6 in team); the tracked headcount is 26.
| Name | Role | Group |
|---|---|---|
Kathryn McCarthy | Manufacturing Engineer | Team |
Joan B. | Clinical Research Associate III | Team |
Stephanie Cavoores | Senior Clinical Field Manager | Team |
Sarala Vallabhaneni | Clinical Research Associate II | Team |
Weber Guerrier Rt | Sr. Clinical Field Manager | Team |
Corwin D. Belfield, MPA | Senior Clinical Research Associate | Team |
Complete people profiles for Instylla
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Instylla
3 dated milestones of Instylla across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Instylla is founded.
- Funding First funding round of $8.1M.
- Funding Latest funding round, Series B, of $21.7M.
Web traffic of Instylla
The website of Instylla (instylla.com) receives about 2K visits a month.
- Monthly visits2K
▼ 63.4% vs previous month
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as Instylla (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Instylla
Complete news archive for Instylla
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Instylla
Instylla was founded in 2017.
Instylla is headquartered in United States.
Instylla is a funded company, having raised a total of $85.51M across 4 funding rounds to date. The company's 1st funding round was a Series A of $8.08M, raised on Jun 2017.
Instylla has 26 employees.
Instylla is focused on the development of next-generation liquid embolics for interventional radiology. Applications are primarily targeted at interventional oncology and peripheral hemostasis. Solutions like Embrace Hydrogel Embolic System are designed for embolization of hypervascular tumors in peripheral arteries. The company aims to advance medical procedures through innovative embolic systems.
Instylla offers Embrace Hydrogel Embolic System and Tembo Embolic System.
Instylla has 8 investors. Key investors include Delos Capital, Excelestar Ventures, Ascension Ventures, CHV, and AMED Ventures.
Instylla operates through Instylla, Inc..